Uppsala
UPPSALA, Sweden, December 6, 2011 -
Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Almac Discovery Ltd., an independent member of the Almac Group Ltd.
UPPSALA, Sweden, September 15, 2011 -
Swedish life science initiative Uppsala BIO has formed a strategic partnering agreement with Roche, the world leading pharmaceuticals and diagnostics company, for Uppsala BIO's open innovation program, BIO-X.
UPPSALA, Sweden, August 23, 2011 -
HighCapacity Instruments,Combining AllergyandAutoimmunity Testing BasedonProvenPhadiaTechnologyforReliability
Today Phadia, the global leader in allergy and autoimmune related diseases diagnostics, announced the launch of Phadia's new allergy and autoimmunity testing instruments; Phadia 2500 and Phadia 5000.
UPPSALA, Sweden and COPENHAGEN, Denmark, August 22, 2011 -
Phadia AB and Biomonitor A/S announced today a collaboration in the field of immunogenicity testing and monitoring of patients treated with biopharmaceutical drugs.
UPPSALA, Sweden, June 20, 2011 -
510(K) Clearance Covers 13 Molecular
Allergen Components
Newly-available tests provide deepest clinical insight into
peanut allergy, as well as allergies to cat dander, dust mite,
Bermuda grass, ragweed, and fungi enabling a significant
improvement in the clinical management of patients with suspected
allergies.
More News
- Recombinant Allergen Components Secure Optimal Immunotherapy Treating Venom Allergy
- New Diagnostic Tool a Potential Life-Saver for Patients with Allergy to Insect Venom
- ImmunoCAP(R) Used in Largest Cross-sectional Allergy Study Ever
- Beactica Announces Fragment-Based Drug Discovery Agreement
- New NICE Guidelines - All Children and Young People With Suspected Food Allergy Should be Offered an Allergy Test
- Phadia Allergy and Autoimmunity Products Commercially Approved in India
- Phadia Acquires Nanjing Wei Kang Le Trade Co., (WKL) in China
- New NIH Guidelines Advocate ImmunoCAP Blood Test to Improve Diagnosis of Food Allergy
- /C O R R E C T I O N — Phadia/
- A Number of Promising New Product Candidates for Cancer Treatment, Within Both Human and Veterinary Oncology
- AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
- Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
- SportSpundit.com Fantasy World Twenty20 Steps Up to the Wicket
- Beactica Announces Drug Discovery Agreement With Cubist Pharmaceuticals
- Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
- Hansoft Launches Version 5.3 at GDC
